⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for monalizumab

Every month we try and update this database with for monalizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung CancerNCT05903092
Small Cell Lung...
SCLC
Extensive Stage...
Durvalumab
Monalizumab
Carboplatin or ...
Etoposide
18 Years - Hoosier Cancer Research Network
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerNCT05221840
Non-Small Cell ...
Durvalumab
Oleclumab
Monalizumab
Placebo
18 Years - AstraZeneca
Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trialNCT04307329
Breast Cancer
Monalizumab
Trastuzumab
18 Years - The Netherlands Cancer Institute
Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trialNCT04307329
Breast Cancer
Monalizumab
Trastuzumab
18 Years - The Netherlands Cancer Institute
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckNCT02643550
Head and Neck N...
Monalizumab
Cetuximab
Anti-PD(L)1
18 Years - Innate Pharma
Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 TrialNCT03801902
Locally Advance...
Locally Recurre...
Stage II Lung C...
Stage III Lung ...
Unresectable Lu...
Accelerated Hyp...
Biospecimen Col...
Computed Tomogr...
Durvalumab
Magnetic Resona...
Monalizumab
Oleclumab
Radiation Thera...
18 Years - National Cancer Institute (NCI)
Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trialNCT04307329
Breast Cancer
Monalizumab
Trastuzumab
18 Years - The Netherlands Cancer Institute
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerNCT04590963
Squamous Cell C...
Monalizumab
Cetuximab
Placebo
18 Years - 130 YearsAstraZeneca
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerNCT03794544
Resectable
Early-stage
NSCLC
Durvalumab
Oleclumab
Monalizumab
Danvatirsen
18 Years - 102 YearsMedImmune LLC
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckNCT02643550
Head and Neck N...
Monalizumab
Cetuximab
Anti-PD(L)1
18 Years - Innate Pharma
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerNCT03794544
Resectable
Early-stage
NSCLC
Durvalumab
Oleclumab
Monalizumab
Danvatirsen
18 Years - 102 YearsMedImmune LLC
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerNCT05221840
Non-Small Cell ...
Durvalumab
Oleclumab
Monalizumab
Placebo
18 Years - AstraZeneca
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerNCT04590963
Squamous Cell C...
Monalizumab
Cetuximab
Placebo
18 Years - 130 YearsAstraZeneca
Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell TransplantationNCT02921685
Hematologic Mal...
Monalizumab
18 Years - 70 YearsInstitut Paoli-Calmettes
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: